# IXICO

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ixico

- Industry: Healthcare
- Headquarters: London, UK
- Website: www.ixico.com
- Total disclosed funding: $1.7M
- Latest round: Series A (Jul 25, 2006)
- Investors on record: 1

## About

Based in the UK, IXICO Ltd. provides specialized services in neuroscience imaging and biomarker analytics through an innovative AI-driven platform focused on enhancing neurological disorder treatments and advancing drug discovery processes.IXICO Ltd., founded in 2004, operates out of London, UK, offering advanced services in neuroscience imaging. The firm underwent a significant transformation in September 2013, merging with Phytopharm in a reverse merger valued at EUR 5.60 million, subsequently becoming publicly listed on the London Stock Exchange under the ticker "IXI". Founder Daniel Rueckert's entrepreneurial background has influenced IXICO's strategic direction, while CEO Giulio Cerroni leads ongoing operations. IXICO has engaged in a total of 5 deals, the most recent funding round being a PIPE of GBP 2.300 mn from CIP Merchant Capital, representing the entirety of their raised capital.IXICO specializes in neuroscience imaging and biomarker analytics, offering a proprietary AI-driven platform designed to enhance the treatment of neurological disorders and streamline drug discovery processes. The IXICO Platform employs advanced, disease-specific algorithms to generate clinical data and insights that facilitate research and development decision-making, mitigate risks in clinical trials, and optimize drug development programs. The company's services cater to a diverse clientele, including leading pharmaceutical companies, innovative biotech firms, scientific consortia, and non-profit organizations focused on neurological diseases. IXICO's platform effectively manages and analyzes clinical trial data while providing precise imaging biomarker measurements related to conditions such as Alzheimer’s, Huntington’s, and Parkinson’s diseases. IXICO operates in various global markets, ensuring a broad reach for its products and services within the biopharmaceutical industry.In the most recent fiscal year 2023, IXICO reported a revenue of GBP 8,177,096.90, alongside an EBITDA of GBP -996,219.50. The company's revenue model is primarily structured around providing specialized services to clients in the biopharmaceutical sector. IXICO engages in direct business-to-business transactions, offering tailored solutions for neurological clinical trials, which may involve subscription-based partnerships or contractual agreements with pharmaceutical and biotech companies. Transactions typically encompass the provision of comprehensive data analytics, imaging biomarker assessments, and trial management services. Clients may engage IXICO for specific projects or ongoing collaborations, reflecting the customized nature of its offerings in the neuroscience domain.IXICO plans to leverage its recent funding of GBP 2.300 mn to enhance its technological capabilities and expand its service offerings. The company aims to introduce new AI-driven products aimed specifically at improving imaging biomarker assessments by the end of 2024. Additionally, IXICO is targeting expansion into key markets in North America and Europe, planning to establish a significant presence there by 2025. The firm’s strategic investments will focus on developing partnerships with pharmaceutical companies in these regions to facilitate innovative clinical trial solutions.

## Funding rounds

- Series A, Jul 25, 2006, $1.7M — YFM Venture Finance Limited

## Investors

- YFM Venture Finance Limited (https://capitalatlas.ai/funds/yfm-venture-finance-limited) — Series A